首页 › 基金 › NEXTBio Capital Management LP › ACET
NEXTBio Capital Management LP 对 ACET 的持仓历史
ADICET BIO INC · 医疗保健
NEXTBio Capital Management LP 在 Q2 2026 的 13F 申报中披露持有 ACET(ADICET BIO INC)157,827 股,市值约 US$1.4M,约占其申报组合的 0.63%,在其申报持仓中市值排名第 22 位。 NEXTBio Capital Management LP 最近 3 个申报季度中有 3 个季度披露了 ACET 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
NEXTBio Capital Management LP 对 ACET 的持仓演变
NEXTBio Capital Management LP 于 Q4 2025 首次披露 ACET 持仓:157,827 股(约 US$1.3M)。 该持仓在 Q2 2026 达到峰值 157,827 股,市值约 US$1.4M。 在 3 次申报中,NEXTBio Capital Management LP 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 157,827 股、市值约 US$1.4M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 157.83K | $1.33M | 新进 |
| Q1 2026 | 157.83K | $1.07M | 持有 |
| Q2 2026 | 157.83K | $1.36M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ACET 与 13F 数据
ACET(ADICET BIO INC)属于医疗保健行业。我们追踪的基金中还有 27 只申报持有 ACET,申报仓位最大的包括:Stonepine Capital Management, LLC (US$2.1M), Carlyle Group Inc. (US$1.6M), REGENERON PHARMACEUTICALS, INC. (US$523K)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ACET 的基金
- Stonepine Capital Management, LLC 245.52K 股 · $2.12M · Q2 2026
- Carlyle Group Inc. 184.29K 股 · $1.59M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 60.51K 股 · $522.82K · Q2 2026
更多关于 NEXTBio Capital Management LP
常见问题
How long has NEXTBio Capital Management LP held ACET?
NEXTBio Capital Management LP has disclosed ACET holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in ACET?
As of Q2 2026, NEXTBio Capital Management LP holds 157.83K shares of ACET (ADICET BIO INC), valued at $1.36M, representing 0.63% of its reported portfolio and ranking #22.
Has NEXTBio Capital Management LP been buying or selling ACET?
In the latest 13F filing (Q2 2026), NEXTBio Capital Management LP held unchanged its position in ACET. The position peaked in Q2 2026 at 157.83K shares.
Which other funds hold ACET?
Other major institutional holders of ACET include Stonepine Capital Management, LLC, Carlyle Group Inc., REGENERON PHARMACEUTICALS, INC., among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.